IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)

This study is testing whether combining immunotherapy with an anti-angiogenic drug (a medication that cuts off blood supply to tumors) as first-line treatment improves survival in patients with advanced or metastatic soft tissue sarcoma (a cancer of connective tissues such as fat, muscle, or nerves). **You may be eligible if...** - You are between 18 and 75 years old - Your soft tissue sarcoma has been confirmed by biopsy and is one of the eligible subtypes: undifferentiated sarcoma, synovial sarcoma, angiosarcoma, fibrosarcoma, smooth muscle sarcoma, liposarcoma (non-well-differentiated), pleomorphic rhabdomyosarcoma, or malignant peripheral nerve sheath tumor - Your disease is locally advanced or metastatic - You have not received prior systemic treatment for advanced disease **You may NOT be eligible if...** - Your sarcoma subtype is not on the eligible list (e.g., Ewing sarcoma, well-differentiated liposarcoma) - You have had prior chemotherapy or targeted therapy for metastatic disease - You have serious heart disease or uncontrolled high blood pressure - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.